MedPath

Gesynta Pharma AB

Gesynta Pharma AB logo
🇸🇪Sweden
Ownership
Holding
Established
2017-01-01
Employees
1
Market Cap
-
Website
http://www.gesynta.se

Clinical Trials

7

Active:3
Completed:4

Trial Phases

2 Phases

Phase 1:5
Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials

Phase 1
5 (71.4%)
Phase 2
2 (28.6%)

A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis

Phase 2
Completed
Conditions
Systemic Sclerosis
Interventions
Drug: Placebo
First Posted Date
2021-02-08
Last Posted Date
2024-08-09
Lead Sponsor
Gesynta Pharma AB
Target Recruit Count
94
Registration Number
NCT04744207
Locations
🇬🇧

Investigator site, Manchester, United Kingdom

🇬🇧

Investigator Site, London, United Kingdom

A Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Dosing of GS-248

Phase 1
Completed
Conditions
Pharmacokinetic
Interventions
Drug: Formulation A GS-248
Drug: Formulation B GS-248
First Posted Date
2020-11-05
Last Posted Date
2021-08-31
Lead Sponsor
Gesynta Pharma AB
Target Recruit Count
14
Registration Number
NCT04617509
Locations
🇸🇪

Clinical Trial Consultants AB, Uppsala, Sweden

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-248

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2019-07-29
Last Posted Date
2023-10-11
Lead Sponsor
Gesynta Pharma AB
Target Recruit Count
72
Registration Number
NCT04036227
Locations
🇸🇪

CTC Clinical Trial Consultants AB, Uppsala, Sweden

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.